These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31056428)

  • 21. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
    Stubbins RJ; Korotev S; Godley LA
    Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatic mutation panels: Time to clear their names.
    Trottier AM; Cavalcante de Andrade Silva M; Li Z; Godley LA
    Cancer Genet; 2019 Jun; 235-236():84-92. PubMed ID: 31101556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic TP53 variants frequently confound germ-line testing results.
    Weitzel JN; Chao EC; Nehoray B; Van Tongeren LR; LaDuca H; Blazer KR; Slavin T; Facmg DABMD; Pesaran T; Rybak C; Solomon I; Niell-Swiller M; Dolinsky JS; Castillo D; Elliott A; Gau CL; Speare V; Jasperson K
    Genet Med; 2018 Aug; 20(8):809-816. PubMed ID: 29189820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
    Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
    BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes.
    Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J;
    Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of genetic susceptibility for breast and ovarian cancer in a non-cancer related study population: secondary germline findings from a Swiss single centre cohort.
    Kraemer D; Azzarello-Burri S; Steindl K; Boonsawat P; Zweier M; Dedes KJ; Joset P; Fink D; Rauch A
    Swiss Med Wkly; 2019 Aug; 149():w20092. PubMed ID: 31422574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
    Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S
    Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board.
    Xavier CB; Link R; Abreu L; Bettoni F; Marson F; Galante PAF; Masotti C; Amano MT; de Molla V; Camargo AA; Asprino PF; Sabbaga J
    Oncologist; 2023 Jul; 28(7):624-627. PubMed ID: 37159554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 major hotspot variants are associated with poorer prognostic features in hereditary cancer patients.
    Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Kho PF; James PA; Spurdle AB
    Cancer Genet; 2019 Jun; 235-236():21-27. PubMed ID: 31296311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO.
    Hoffman TL; Kershberg H; Goff J; Holmquist KJ; Haque R; Alvarado M
    Fam Cancer; 2023 Apr; 22(2):225-235. PubMed ID: 36261688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
    Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
    Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
    Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
    Weidner AE; Liggin ME; Zuniga BI; Tezak AL; Wiesner GL; Pal T
    Cancer; 2020 Apr; 126(8):1651-1655. PubMed ID: 31967672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole Exome Sequencing Identifies Candidate Genes Associated with Hereditary Predisposition to Uveal Melanoma.
    Abdel-Rahman MH; Sample KM; Pilarski R; Walsh T; Grosel T; Kinnamon D; Boru G; Massengill JB; Schoenfield L; Kelly B; Gordon D; Johansson P; DeBenedictis MJ; Singh A; Casadei S; Davidorf FH; White P; Stacey AW; Scarth J; Fewings E; Tischkowitz M; King MC; Hayward NK; Cebulla CM
    Ophthalmology; 2020 May; 127(5):668-678. PubMed ID: 32081490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.
    Pearlman R; Frankel WL; Swanson B; Zhao W; Yilmaz A; Miller K; Bacher J; Bigley C; Nelsen L; Goodfellow PJ; Goldberg RM; Paskett E; Shields PG; Freudenheim JL; Stanich PP; Lattimer I; Arnold M; Liyanarachchi S; Kalady M; Heald B; Greenwood C; Paquette I; Prues M; Draper DJ; Lindeman C; Kuebler JP; Reynolds K; Brell JM; Shaper AA; Mahesh S; Buie N; Weeman K; Shine K; Haut M; Edwards J; Bastola S; Wickham K; Khanduja KS; Zacks R; Pritchard CC; Shirts BH; Jacobson A; Allen B; de la Chapelle A; Hampel H;
    JAMA Oncol; 2017 Apr; 3(4):464-471. PubMed ID: 27978560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ATM whole gene deletion in an Italian family with hereditary pancreatic cancer: Challenges to cancer risk prediction associated with an 11q22.3 microdeletion.
    Arts HH; Lynch L; Grafodatskaya D; Eng B; Malloy L; Duck J; White R; Woodside C; Bell K; Zbuk KM; McCready E
    Cancer Genet; 2020 Jan; 240():1-4. PubMed ID: 31671381
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Stolarova L; Kleiblova P; Janatova M; Soukupova J; Zemankova P; Macurek L; Kleibl Z
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.